Drug intelligence / Profile preview

68Ga-EVS459

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-EVS459 is a diagnostic radiopharmaceutical, specifically a gallium-68-labeled radio-ligand imaging agent developed by Novartis Pharmaceuticals. It is designed for positron emission tomography (PET) imaging to detect and evaluate certain cancers, including advanced high-grade serous ovarian cancer and locally advanced or metastatic non-squamous non-small cell lung carcinoma. The agent enables visualization of tumors for diagnosis and treatment planning. Its mechanism of action involves targeting tumor-associated molecular markers to facilitate PET imaging in oncology settings[1][2][4].

Other names: [68Ga]Ga-EVS459Gallium-68 EVS459Gallium68 EVS459Gallium 68 EVS459

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on 68Ga-EVS459.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-EVS459.

Explore the full profile